Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zenith DrugsNSE:ZENITHDRUG -4.48%36 EV-to-FCF is -28.84 as of Jul. 17, 2026. GuruFocus rates NSE:ZENITHDRUG with a GF Score™ of 36/100. The stock has 8 warning signs investors should review. Among 564 Drug Manufacturers companies, Zenith Drugs ranks worse than 177304.79% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Zenith Drugs's Enterprise Value is ₹1,408 Mil.
Zenith Drugs's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was ₹-49 Mil. Therefore, Zenith Drugs's EV-to-FCF for today is -28.84.
The historical rank and industry rank for Zenith Drugs's EV-to-FCF or its related term are showing as below:
NSE:ZENITHDRUG'
s EV-to-FCF Range Over the Past 10 Years
Min: -29.67 Med: -5.75 Max: -2.94
Current: -29.67
During the past 6 years, the highest EV-to-FCF of Zenith Drugs was -2.94. The lowest was -29.67. And the median was -5.75.
NSE:ZENITHDRUG's EV-to-FCF is ranked worse than 100% of 564
companies
in the Drug Manufacturers industry
Industry Median: 20.815
vs NSE:ZENITHDRUG: -29.67
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Zenith Drugs's PE Ratio (TTM) for today is calculated as:
Zenith Drugs's share price for today is ₹50.10.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Zenith Drugs's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹2.300.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Zenith Drugs EV-to-FCF Related Terms
Zenith Drugs EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Zenith Drugs's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Zenith Drugs's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zenith Drugs EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zenith Drugs's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Zenith Drugs's EV-to-FCF falls into.
Zenith Drugs's current Enterprise Value is ₹1,408 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Zenith Drugs's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was ₹-49 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zenith Drugs (NSE:ZENITHDRUG) has a EV-to-FCF of -28.84 as of Jul. 17, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Zenith Drugs and its competitors. According to the industry distribution chart, Zenith Drugs ranks #999999 out of 564 companies in the Drug Manufacturers industry.
Is Zenith Drugs' EV-to-FCF too high?
Zenith Drugs' current EV-to-FCF is -28.84. Based on the distribution chart, Zenith Drugs ranks #999999 out of 564 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Zenith Drugs has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Zenith Drugs' EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Zenith Drugs ranks #999999 out of 564 companies for EV-to-FCF. This places Zenith Drugs in the lower half of its industry. The industry median EV-to-FCF is 20.82. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.82, based on 564 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Zenith Drugs and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zenith Drugs's current EV-to-FCF is -28.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zenith Drugs stock overvalued right now?
Zenith Drugs (NSE:ZENITHDRUG) has a current EV-to-FCF of -28.84. The current EV-to-FCF is -28.84. Zenith Drugs' overall GF Score™ is 36/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Zenith Drugs (NSE:ZENITHDRUG), the current EV-to-FCF is -28.84 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Zenith Drugs Ltd is a pharmaceutical manufacturing and trading company. It offers a wide range of formulations in various forms such as ORS Powder, Liquid Orals, Ointments, Liquid Externals, Creams, Gels, Capsules, and Tablets. It is also into Generic Medicines.
36GF Score
Get the complete analysis for NSE:ZENITHDRUG
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ZENITHDRUG has been successfully added to your 
